True precision medicine in immuno-oncology, challenges, and opportunities
March 18 @ 09:00 – 09:30 CET
On March 18, Uppsala University Associate Professor Sara Mangsbo will talk about how the future of cancer therapy is becoming personal. Sara co-founded Strike Pharma to further develop the Uppsala University and SciLifeLab Drug Discovery platform co-developed ADAC technology (Adaptable Drug Affinity Conjugates).
With current diagnostic tools also, immunotherapy can and should enter the omics-field and the developed delivery platform envisions a truly patient tailored neoantigen cancer vaccine strategy, ensuring that the body becomes the factory to generate tumor-specific T cells, that can find and destroy tumor cells regardless of the location in the body. With a cost and time efficient “True Precision Medicine” approach, tailored therapeutics will be a realistic future, ultimately lowering the healthcare burden for a sustainable future.
Sara Mangsbo is a Senior Lecturer in Antibody Drugs at Uppsala University at the Department of Pharmacy. She has her education background with a PhD in Clinical Immunology Uppsala University. Sara has since completed her postdoctoral studies at Leiden University Medical Center and started her own research group at Uppsala University in 2016. Her work focuses on the development and immunological characterization of novel immunotherapies and therapeutic combination strategies for drug discovery. Sara has previously also held a brand lead position in Immuno-oncology at Astra Zeneca’s marketing division and co-founded the drug development and service company startups Immuneed AB and VivoLogica AB (current board member). The drug development platform from Immuneed was acquired by the Norwegian pharmaceutical company Ultimovacs in 2018.
In late 2020, Sara co-founded Strike Pharma AB. Strike Pharma develops a novel next generation Antibody-Drug Conjugate (ADC) technology, the ADAC technology. ADACs are short for Adaptable Drug Affinity Conjugates and are built to improve deliver tailored made synthetic peptides to specific cell types for improved immune modulation. Using the ADAC platform, efficient delivery and extended half-life of patient tailored peptide therapeutics will ensure that the body becomes the factory, producing billions of T cells that can find and destroy tumors cells regardless of the location in the body.
“Clinical Talks” has been renewed for yet another exciting, innovative, and enlightening season. This season will focus on sustainable innovations within Life Sciences, that have the potential to contribute to a better climate friendly future for our future generations. Also new this year is that the seminar is co-organized in a collaboration between SciLifeLab and KI Innovations .
Season 5, will be held September 2021 until March 2022 with scheduled Talks, during Friday mornings 09-09:30 am via ZOOM (with some time-zone friendly adjustments for our international speakers). Each session consists of a talk given by our invited speaker followed by Q&A. The seminar is an open educational seminar series for our ever-expanding Life Science community.